Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair

Xenon Pharmaceuticals (NASDAQ:XENE)‘s stock had its “outperform” rating reaffirmed by analysts at William Blair in a report issued on Friday,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Other analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 target price for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Price Performance

XENE opened at $37.02 on Friday. The business has a fifty day simple moving average of $39.27 and a 200 day simple moving average of $40.31. The company has a market capitalization of $2.82 billion, a PE ratio of -13.13 and a beta of 1.20. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.05. Equities analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now owns 31,302 shares of the company’s stock, valued at $1,267,731. This represents a 34.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders sold a total of 57,492 shares of company stock worth $2,334,969 in the last ninety days. 5.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. increased its holdings in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 641 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Xenon Pharmaceuticals in the 4th quarter worth about $63,000. Quarry LP acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $78,000. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $101,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 487 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.